Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma(MUK-six): a multicentre, open-label, phase 1/2 trial.
Popat R et al. Lancet Haematol. 2016 Nov 11. pii: S2352-3026(16)30165-X. doi: 10.1016/S2352-3026(16)30165-X. [Epub ahead of print].

A phase IIb trial of vorinostat in combination with lenalidomide and dexamethasone in patients with multiple myeloma refractory to previous lenalidomide-containing regimens.
Sanchez L et al. Br J Haematol. 2016 Nov 18. doi: 10.1111/bjh.14429. [Epub ahead of print].

Elotuzumab with lenalidomide and dexamethasone for Japanese patients with relapsed/refractory multiple myeloma: phase 1 study.
Iida S et al. Int J Hematol. 2016 Nov 15. [Epub ahead of print].

Deacetylase Inhibitors as a Novel Modality in the Treatment of Multiple Myeloma.
Richardson PG et al. Pharmacol Res. 2016 Nov 21. pii: S1043-6618(16)31192-6. doi: 10.1016/j.phrs.2016.11.020. [Epub ahead of print].